Inherited variations in AR, ESR1, and ESR2 genes are not associated with prostate cancer aggressiveness or with efficacy of androgen deprivation therapy

Cancer Epidemiology Biomarkers and Prevention

Volumn 19, Issue 7, 2010, Pages 1871-1878

  Sun, Tong ^a   Lee, Gwo Shu Mary ^a   Werner, Lillian ^a   Pomerantz, Mark ^a   Oh, William K ^a,b   Kantoff, Philip W ^a   Freedman, Matthew L ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; ANTIANDROGEN; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; GONADORELIN; ESTROGEN RECEPTOR ALPHA, HUMAN;

ADULT; AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; CANCER HORMONE THERAPY; CANCER SURGERY; DRUG EFFICACY; GENE LOCUS; GENETIC VARIABILITY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; ORCHIECTOMY; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; SINGLE NUCLEOTIDE POLYMORPHISM; GENETIC PREDISPOSITION; GENETICS; PATHOLOGY; PROSTATIC NEOPLASMS; RISK FACTOR; TUMOR INVASION;

ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; GENETIC PREDISPOSITION TO DISEASE; GENETIC VARIATION; GENOTYPE; HUMANS; MALE; NEOPLASM INVASIVENESS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSTATECTOMY; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; RISK FACTORS;

EID: 77954498376     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-10-0216     Document Type: Article

References (25)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin 2009;59:225-49.
2. Andriole GL, Crawford ED, Grubb RL III, et al. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 2009;360:1310-9.
3. Pronzato P, Rondini M. Hormonotherapy of advanced prostate cancer. Ann Oncol 2005;4:iv80-4.
4. Singer EA, Golijanin DJ, Miyamoto H, Messing EM. Androgen deprivation therapy for prostate cancer. Expert Opin Pharmacother 2008;9:211-28.
5. Ekman P. The prostate as an endocrine organ: androgens and estrogens. Prostate Suppl 2000;10:14-8.
6. Ricke WA, Wang Y, Cunha GR. Steroid hormones and carcinogenesis of the prostate: the role of estrogens. Differentiation 2007;75:871-82.
7. Huang H, Tindall DJ. The role of the androgen receptor in prostate cancer. Crit Rev Eukaryot Gene Expr 2002;12:193-207.
8. Bonkhoff H, Berges R. The evolving role of oestrogens and their receptors in the development and progression of prostate cancer. Eur Urol 2009;55:533-42.
9. Golias Ch, Iliadis I, Peschos D, Charalabopoulos K. Amplification and co-regulators of androgen receptor gene in prostate cancer. Exp Oncol 2009;31:3-8.
10. Dutt SS, Gao AC. Molecular mechanisms of castration-resistant prostate cancer progression. Future Oncol 2009;5:1403-13.
11. Freedman ML, Pearce CL, Penney KL, et al. Systematic evaluation of genetic variation at the androgen receptor locus and risk of prostate cancer in a multiethnic cohort study.Am J Hum Genet 2005;76:82-90.
12. Thellenberg-Karlsson C, Lindström S, Malmer B, et al. Estrogen receptor β polymorphism is associated with prostate cancer risk. Clin Cancer Res 2006;12:1936-41.
13. Nicolaiew N, Cancel-Tassin G, Azzouzi AR, et al. Association between estrogen and androgen receptor genes and prostate cancer risk. Eur J Endocrinol 2009;160:101-6.
14. Chae YK, Huang HY, Strickland P, Hoffman SC, Helzlsouer K. Genetic polymorphisms of estrogen receptors α and β and the risk of developing prostate cancer. PLoS One 2009;4:e6523.
15. Chen YC, Kraft P, Bretsky P, et al. Sequence variants of estrogen receptor β and risk of prostate cancer in the National Cancer Institute Breast and Prostate Cancer Cohort Consortium. Cancer Epidemiol Biomarkers Prev 2007;16:1973-81.
16. McIntyre MH, Kantoff PW, Stampfer MJ, et al. Prostate cancer risk and ESR1 TA, ESR2 CA repeat polymorphisms. Cancer Epidemiol Biomarkers Prev 2007;16:2233-6.
17. Oh WK, Hayes J, Evan C, et al. Development of an integrated prostate cancer research information system. Clin Genitourin Cancer 2006;5:61-6.
18. Penney KL, Salinas CA, Pomerantz M, et al. Evaluation of 8q24 and 17q risk loci and prostate cancer mortality. Clin Cancer Res 2009;15:3223-30.
19. Patterson N, Price AL, Reich D. Population structure and eigenanalysis. PLoS Genet 2006;2:e190.
20. D'Amico AV, Whittington R, Malkowicz SB, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998;280:969-74.
21. Ross RW, Oh WK, Xie W, et al. Inherited variation in the androgen pathway is associated with the efficacy of androgen-deprivation therapy in men with prostate cancer. J Clin Oncol 2008;26:842-7.
22. Ross RW, Xie W, Regan MM, et al. Efficacy of androgen deprivation therapy (ADT) in patients with advanced prostate cancer: association between Gleason score, prostate-specific antigen level, and prior ADT exposure with duration of ADT effect. Cancer 2008;112:1247-53.
23. de Bakker PI, Yelensky R, Pe'er I, Gabriel SB, Daly MJ, Altshuler D. Efficiency and power in genetic association studies. Nat Genet 2005;37:1217-23.
24. Available from: http://www.broad.mit.edu/mpg/haploview.
25. Lindström S, Adami HO, Bälter KA, et al. Inherited variation in hormone-regulating genes and prostate cancer survival. Clin Cancer Res 2007;13:5156-61.